MORAb-009 Phase II Study for Treatment of Mesothelioma

In March 2009, the biopharmaceutical company Morphotek announced they were beginning a Phase II study of an experimental antibody treatment known as MORAb-009. The study will evaluate MORAb-009 as a first-line treatment for patients that have been diagnosed with mesothelioma, a serious form of lung cancer caused by exposure to asbestos.

In 2006, MORAb-009 received investigational new drug (IND) application status from the Food and Drug Administration (FDA).

Morphotek is currently seeking up to 86 participants to participate at three northeastern hospitals: Christiana Care Health System in Newark, Delaware; NIH/National Cancer Institute in Bethesda, Maryland; and NYU Medical Center in New York City.

Exposure to asbestos is known to cause serious diseases such as mesothelioma, asbestos-related lung cancer and asbestosis.

Weitz & Luxenberg is a leading plaintiffs' law firm that has represented people affected by mesothelioma for over 20 years. Men and women diagnosed with mesothelioma caused by asbestos exposure may be entitled to compensation from the companies responsible for their disease.

If you would like a free consultation or more information about your legal options, please complete the form below, and a representative of our law firm will contact you as soon as possible.